Illumina, Inc.
Financials
Valuation Metrics
Illumina, Inc.'s Market Cap is $36.24B. At end of 2025 it was $20.07B. Ranked #397 of 3,121 in US market (top 13%), #112 of 1,463 on NASDAQ (top 8%), #25 of 205 in Health Care Equipment & Services (top 12%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $36.24B | US#397/3,121 Sec#25/205 |
| Revenue | $4.49B | US#946/3,121 Sec#56/205 |
| Net Income | $825M | US#625/3,121 Sec#35/205 |
| Total Assets | $6.65B | US#1,246/3,121 Sec#55/205 |
| Net Assets | $2.84B | US#1,017/3,121 Sec#53/205 |
| Employees | 8,600 | US#940/3,121 Sec#71/205 |
| Value | ||
| P/E | 43.93x | US#1,876/3,121 Sec#93/205 |
| P/B | 12.77x | US#2,703/3,121 Sec#175/205 |
| P/S | 8.07x | US#2,616/3,121 Sec#174/205 |
| EV/EBITDA | 27.68x | US#2,182/3,121 Sec#115/205 |
| FCF Yield | 2.59% | US#1,935/3,121 Sec#115/205 |
| Profitability | ||
| ROE | 29.07% | US#315/3,121 Sec#15/205 |
| ROA | 12.41% | US#328/3,121 Sec#19/205 |
| Op. Margin | 20.97% | US#855/3,121 Sec#25/205 |
| Revenue Growth | 4.93% | US#1,818/3,121 Sec#133/205 |
| Earnings Growth | -34.42% | US#1,657/3,121 Sec#86/205 |
| Financial Health | ||
| Debt Ratio | 134.32% | US#1,386/3,121 Sec#126/205 |
| Total Debt | $2.53B | US#1,041/3,121 Sec#49/205 |
| FCF | $939M | US#615/3,121 Sec#36/205 |
| Cash | $1.04B | US#663/3,121 Sec#37/205 |
| Current Ratio | 1.80x | US#1,390/3,121 Sec#120/205 |
| Net Debt/EBITDA | 1.09x | US#1,001/3,121 Sec#56/205 |
| Performance | ||
| 1Y Return | 132.51% | US#115/3,121 Sec#11/205 |
| 1M Return | 16.85% | US#40/3,121 Sec#8/205 |
| From 52W High | -3.87% | US#33/3,121 Sec#9/205 |
| 1Y MDD | -25.66% | US#1,100/3,121 Sec#36/205 |
| Trading | ||
| Volume | 2,777,825 shares | US#475/3,121 Sec#22/205 |
| Trading Value | $671M | US#104/3,121 Sec#7/205 |
| Per Share | ||
| EPS | $5.45 | US#625/3,121 Sec#38/205 |
| BPS | $18.76 | US#1,304/3,121 Sec#72/205 |
Company Info
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.